HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable.

Journal Article

Many candidate HIV vaccines are designed to primarily elicit T cell responses. Although repeated immunization with the same vaccine boosts Ab responses, the benefit for T cell responses is ill defined. We compared two immunization regimens that include the same recombinant adenoviral serotype 5 (rAd5) boost. Repeated homologous rAd5 immunization fails to increase T cell responses, but increases gp140 Ab responses 10-fold. DNA prime, as compared with rAd5 prime, directs long-term memory CD8(+) T cells toward a terminally differentiated effector memory phenotype with cytotoxic potential. Based on the kinetics of activated cells measured directly ex vivo, the DNA vaccination primes for both CD4(+) and CD8(+) T cells, despite the lack of detection of the latter until after the boost. These results suggest that heterologous prime-boost combinations have distinct immunological advantages over homologous prime-boosts and suggest that the effect of DNA on subsequent boosting may not be easily detectable directly after the DNA vaccination.

Full Text

Duke Authors

Cited Authors

  • De Rosa, SC; Thomas, EP; Bui, J; Huang, Y; deCamp, A; Morgan, C; Kalams, SA; Tomaras, GD; Akondy, R; Ahmed, R; Lau, C-Y; Graham, BS; Nabel, GJ; McElrath, MJ; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network,

Published Date

  • September 15, 2011

Published In

Volume / Issue

  • 187 / 6

Start / End Page

  • 3391 - 3401

PubMed ID

  • 21844392

Electronic International Standard Serial Number (EISSN)

  • 1550-6606

Digital Object Identifier (DOI)

  • 10.4049/jimmunol.1101421

Language

  • eng

Conference Location

  • United States